When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 and PD-L1 inhibitors.
Patients with extensive-stage small cell lung cancer (ES-SCLC) saw significant survival benefits when treated with either PD-1 or PD-L1 inhibitors combined with chemotherapy, according to a new meta-analysis.1
Researchers found no significant difference in OS and PFS for patients with ES-SCLC. | Image credit: utah51 – stock.adobe.com
The study was published in Frontiers in Oncology and included 3559 patients with ES-SCLC across 8 randomized clinical trials (RCTs). After comparing the 2 immunotherapy approaches, researchers found no significant difference in overall survival (OS) or progression-free survival (PFS) between them.
“The present study enriched the research data on PD-1 inhibitors in the first-line treatment of ES-SCLC after the inclusion of the results of tislelizumab and toripalimab, but PD-1 + Chemo versus PD-L1 + Chemo did not produce a significant improvement in OS and PFS,” the authors said.
Patients who received PD-1 plus chemotherapy had a 29% reduced risk of death compared with those receiving chemotherapy alone, while those treated with PD-L1 plus chemotherapy saw a 28% reduction in mortality risk. Both treatment combinations significantly improved PFS, increasing by 41% with PD-1 inhibitors and 27% with PD-L1 inhibitors, compared with chemotherapy alone.
In indirect comparisons, researchers did not find a significant advantage of one inhibitor over the other in terms of efficacy (OS: HR, 0.99; 95% CI, 0.86-1.1; PFS: HR, 0.80; 95% CI, 0.61-1.0) or safety (HR, 1.0; 95% CI, 0.93-1.1) when added to chemotherapy. They noted that more research is needed to see how similar or different their efficacy and safety are in treating ES-SCLC.
Regarding safety, neither PD-1 nor PD-L1 inhibitors significantly increased the incidence of severe treatment-related adverse events (TRAEs) compared with chemotherapy alone, the authors found. The likelihood of experiencing grade 3 or higher TRAEs was nearly identical between the 2 treatments (HR, 1.0; 95% CI, 0.93-1.1), reinforcing the idea that both options provide added survival benefits without additional safety concerns. However, as PD-1 inhibitors block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, the authors said the treatment option may lead to a higher incidence of AEs.2
Additionally, a subgroup analysis indicated that patients with ES-SCLC with higher PD-L1 expression levels (≥ 1%) may benefit slightly more from PD-1 inhibitors, while those with lower PD-L1 expression (< 1%) appeared to respond better to PD-L1 inhibitors.1 However, researchers cautioned against using PD-L1 expression as a definitive marker for treatment selection until further research confirms these findings.
A 2020 meta-analysis published in Thoracic Cancer included 4 of the 8 studies analyzed—KEYNOTE-604, IMpower133, EA5161, and CASPIAN—but came to a different conclusion about safety.3
While PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improved survival in ES-SCLC, they were also linked to an increased risk of immune-related AEs (imAEs). Compared with chemotherapy alone, patients who received either combination therapy saw an almost quadrupled increase in all-grade imAEs (HR, 3.77; 95% CI, 1.99-7.15; P < .0001) and a sevenfold increase in severe imAEs, defined as grade 3 or higher (HR, 7.01; 95% CI, 2.48-19.81; P = .0002).
The current study did not assess how these treatments impact quality of life, an important factor for patients.1 According to the authors, additional research with larger, well-controlled clinical trials is needed to confirm these findings.
References
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
ASCO GU Posters Address Cost-Effectiveness, Implementation Barriers for New mUC Treatments
February 13th 2025Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into practice due to high costs and a lack of targeted initiatives to aid health care providers with integration.
Read More